Lyell Immunopharma to issue 625,000 shares upon achieving CAR T-cell clinical milestone

Lyell Immunopharma, Inc.

Milestone for ImmPACT's next-gen CAR T-cell candidate achieved on June 20, 2025.
625,000 shares of common stock (post-1-for-20 reverse split) to be issued to ImmPACT securityholders.
Shares issued in private placement exempt under Section 4(a)(2) of the Securities Act.
Issuance is contingent consideration from the previously completed ImmPACT Bio merger.

item 3.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.